Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

922 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tecovirimat concentrations and viral suppression in seminal fluid from patients with mpox.
Tempestilli M, Mondi A, Matusali G, Mariotti D, Pinnetti C, Beccacece A, Cimini E, Mazzotta V, Carletti F, Faccendini P, Maggi F, Girardi E, Nicastri E, Vaia F, Antinori A. Tempestilli M, et al. Among authors: antinori a. Lancet Infect Dis. 2023 May;23(5):531-532. doi: 10.1016/S1473-3099(23)00214-1. Epub 2023 Mar 30. Lancet Infect Dis. 2023. PMID: 37004668 No abstract available.
Asymptomatic Mpox Virus Infection in Subjects Presenting for MVA-BN Vaccine.
Matusali G, Mazzotta V, Piselli P, Bettini A, Colavita F, Coen S, Vaia F, Girardi E, Antinori A, Maggi F. Matusali G, et al. Among authors: antinori a. Clin Infect Dis. 2023 Nov 17;77(10):1483-1484. doi: 10.1093/cid/ciad414. Clin Infect Dis. 2023. PMID: 37417243 Free PMC article. No abstract available.
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Rossotti R, Gagliardini R, Saracino A, Lo Caputo S, Sala M, Quiros-Roldan E, Mussini C, Girardi E, Cozzi-Lepri A, Antinori A, Puoti M; NoCo Study of the Icona cohort. d'Arminio Monforte A, et al. Among authors: antinori a. Liver Int. 2023 Oct;43(10):2130-2141. doi: 10.1111/liv.15700. Epub 2023 Aug 31. Liver Int. 2023. PMID: 37649460 Free article.
Mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications.
Pinnetti C, Cimini E, Mazzotta V, Matusali G, Vergori A, Mondi A, Rueca M, Batzella S, Tartaglia E, Bettini A, Notari S, Rubino M, Tempestilli M, Pareo C, Falasca L, Del Nonno F, Scarabello A, Camici M, Gagliardini R, Girardi E, Vaia F, Maggi F, Agrati C, Antinori A. Pinnetti C, et al. Among authors: antinori a. Lancet Infect Dis. 2024 Feb;24(2):e127-e135. doi: 10.1016/S1473-3099(23)00482-6. Epub 2023 Sep 28. Lancet Infect Dis. 2024. PMID: 37778364 Review.
Pharyngo-tonsillar involvement of Mpox in a cohort of men who have sex with men (MSM): A serious risk of missing diagnosis.
Pinnetti C, Mondi A, Mazzotta V, Vita S, Carletti F, Aguglia C, Beccacece A, Vergori A, Gagliardini R, Specchiarello E, Ascoli Bartoli T, Baldini F, Giancola ML, Valli MB, D'Abramo A, Gebremeskel Teklè S, Fontana C, Garbuglia AR, Girardi E, Maggi F, Vaia F, Nicastri E, Antinori A. Pinnetti C, et al. Among authors: antinori a. J Infect Public Health. 2024 Jan;17(1):130-136. doi: 10.1016/j.jiph.2023.11.015. Epub 2023 Nov 15. J Infect Public Health. 2024. PMID: 38000313 Free article.
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Salpini R, Piermatteo L, D'Anna S, Carrara S, Malagnino V, Mazzotta V, Brancaccio G, Marchetti GC, Rosselli Del Turco E, Rossotti R, Mussini C, Antinori A, Lo Caputo S, Ceccherini Silberstein F, Gaeta GB, Svicher V, Puoti M; Icona Foundation Study Group. d'Arminio Monforte A, et al. Among authors: antinori a. Liver Int. 2024 Feb;44(2):603-613. doi: 10.1111/liv.15804. Epub 2023 Dec 15. Liver Int. 2024. PMID: 38100128 Free article.
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
Ogbuagu O, Segal-Maurer S, Ratanasuwan W, Avihingsanon A, Brinson C, Workowski K, Antinori A, Yazdanpanah Y, Trottier B, Wang H, Margot N, Dvory-Sobol H, Rhee MS, Baeten JM, Molina JM; GS-US-200-4625 investigators. Ogbuagu O, et al. Among authors: antinori a. Lancet HIV. 2023 Aug;10(8):e497-e505. doi: 10.1016/S2352-3018(23)00113-3. Epub 2023 Jul 11. Lancet HIV. 2023. PMID: 37451297 Clinical Trial.
922 results